Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on July 8th, 2014% (NIST.gov)
8 July 2014. National Institutes of Health is awarding $24 million to eight academic medical centers for research on genomic factors behind people developing or avoiding Alzheimer’s disease. Recipients of the four-year grants are Boston University, Case Western Reserve University in Cleveland, Columbia University in New York, University of Miami, University of . . . → Read More: NIH Funds $24 Million for Genetic Links to Alzheimer’s
By Alan, on December 26th, 2012% (National Institute of Mental Health)
Medical researchers at University of Pennsylvania in Philadelphia developed an algorithm based on magnetic resonance imaging (MRI) to differentiate cases of Alzheimer’s disease from front temporal lobe degeneration, which has similar dementia symptoms. The findings from the research team led by postdoctoral fellow and first author Corey McMillan . . . → Read More: MRI Helps Screen Alzheimer’s, Brain Degeneration Dementia
By Alan, on December 5th, 2012% (National Institute of Mental Health)
A patient in the early stages of Alzheimer’s disease at Johns Hopkins medical center in Baltimore received an implanted deep-brain stimulation device, the first such surgery in the U.S. The implant is part of a clinical trial testing the deep brain stimulation device for Alzheimer’s disease patients made . . . → Read More: U.S. Alzheimer’s Patient Implanted with Deep Brain Pacemaker
By Alan, on January 10th, 2011% (National Institute of Mental Health)
Opko Health Inc., a biotechnology company in Miami, Florida, said today it has a collaboration agreement with the drug manufacturer Bristol-Myers Squibb Company for Opko’s diagnostic test technology. Opko’s blood tests are being developed from its technology that identifies biomarkers for a range of diseases including neurodegenerative disorders.
. . . → Read More: Bristol-Myers Squibb, Biotech Partner on Alzheimer’s Test
By Alan, on August 11th, 2010% Alectos Therapeutics Inc. in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company Merck & Co. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer’s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and . . . → Read More: Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.